Phase Ib Study of Intratumoral CAVATAK(TM) (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

A Phase 1b trial entitled MITCI (Melanoma Intra-Tumoral Cavatak and Ipilimumab) to investigate the use of CAVATAK® in combination with Ipilimumab (Yervoy®) in patients with advanced melanoma is underway at Providence Cancer Centre in Portland, Oregon; Oncology Specialists Institute in Chicago, Illinois and John Wayne Cancer Institute in Santa Monica, California.

The trial is designed to evaluate the safety and tolerability of the established dose of intratumoural CAVATAK in combination with Yervoy® in 26 patients with late-stage melanoma for whom Yervoy® would be considered the standard of care.
Investigators will also assess evidence of anti-cancer activity, including response rates and bio-markers of anti-tumour immunity.

Participate in a Clinical Trial

Learn More